Susquehanna International Group, LLP Enlivex Therapeutics Ltd. Transaction History
Susquehanna International Group, LLP
- $568 Billion
- Q1 2024
A detailed history of Susquehanna International Group, LLP transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 67,943 shares of ENLV stock, worth $89,684. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,943
Previous 27,925
143.31%
Holding current value
$89,684
Previous $75,000
242.67%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ENLV
# of Institutions
23Shares Held
324KCall Options Held
22.8KPut Options Held
29.1K-
Morgan Stanley New York, NY72.1KShares$95,1980.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny69.9KShares$92,2530.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il55.5KShares$73,2930.0% of portfolio
-
Act Capital Management, LLC Wayne, PA15KShares$19,8000.09% of portfolio
-
Geode Capital Management, LLC Boston, MA10.4KShares$13,7540.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $24.3M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...